Fc-Elabela mitigates heart failure without liver and renal toxicity in mice
Our results demonstrate that Fc-ELA-21 improves systolic heart failure by activating VEGFR3 signaling and suggest a mechanism for cross-talk between the APJ receptor and VEGFR3 in myocardial infarction MI. Moreover, Fc-ELA-21 is safe <i>in vivo</i>. Hence, the administration of Fc-ELA-21 fusion protein could be a novel therapeutic for systolic heart failure.
Authors
- Midrar Ullah
- Huifen Zhou (ORCID: https://orcid.org/0000-0002-4863-8041)
- Quan Wang (ORCID: https://orcid.org/0000-0002-9808-5035)
- Qingbin Zhao
- Da‐Wei Gong
- Ishtiaq Jeelani (ORCID: https://orcid.org/0000-0001-9903-6326)
- Hui Chen (ORCID: https://orcid.org/0000-0003-0145-3944)
- Chen Ling (ORCID: https://orcid.org/0000-0003-1527-1471)
- Saleem Ahmad (ORCID: https://orcid.org/0000-0002-8812-2875)
Institutions
- University of Maryland, Baltimore (US)
- University of California, Irvine (US)
- Xianning Central Hospital (CN)
- Hubei University of Science and Technology (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- University of Kansas Medical Center (US)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.3389/fphar.2025.1555728
- Citations
- 2
- Primary Topic
- Apelin-related biomedical research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Health Commission of Hubei Province
- National Natural Science Foundation of China